Satellos Bioscience Inc. announced positive preclinical data showing SAT-3247 can improve skeletal muscle function in multiple mouse models of muscle degeneration. The preclinical data presented show the broad potential of SAT-3247 to improve skeletal muscle function as has been demonstrated in three mouse models of muscle degeneration: mdx model of Duchenne muscular dystrophy (DMD), FLExDUX4 model of facioscapulohumeral muscular dystrophy (FSHD), and a muscle injury model in wildtype mice. In all instances, treatment with SAT-3247 over a three-to-four-week period resulted in a statistically significant improvement in muscle force versus animals receiving placebo.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.47 CAD | -2.08% | +6.82% | +9.30% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.30% | 38.84M | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.70% | 21.25B | |
-6.03% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+5.10% | 13.94B | |
+37.57% | 12.54B |
- Stock Market
- Equities
- MSCL Stock
- News Satellos Bioscience Inc.
- Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference